Osaka, Japan – February 19, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approval by the Ministry of Health, Labour and Welfare (MHLW) for Tadalafil tablets (the branded ... Read More
Company Strengthens Its Generic Portfolio with Rapid Product Expansion
Maple Grove, MN – February 19, 2020 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has expanded its generic portfolio with the recent launch of three ... Read More
Awardees Selected for Their Commitment to Patients and Effort in Advancing the Pharmacy Profession
Maple Grove, MN – February 18, 2020 – Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) are ... Read More
Osaka, Japan – February 17, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 15 generic drugs with 31 ... Read More
Maple Grove, MN – January 28, 2020 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Clonidine Hydrochloride Extended-Release Tablets in 0.1 mg strength. Upsher-Smith’s product is AB1-rated to the branded product, KAPVAY® (clonidine ... Read More
Maple Grove, MN – January 13, 2020 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Haloperidol Tablets, USP in 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg and 20 mg strengths. ... Read More
Maple Grove, MN – January 10, 2020 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Fluvoxamine Maleate Tablets in 25 mg, 50 mg and 100 mg strengths.
The fluvoxamine tablet market had U.S. sales ... Read More
Osaka, Japan – December 12, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of two generic drugs with five strengths. They will be launched sequentially ... Read More
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending the 2019 Annual Meeting of the American Epilepsy Society (AES) December 6-10, 2019 in Baltimore, MD. Meeting attendees are encouraged to visit booth #526 ... Read More
Program Provides Access and Affordability for Patients Seeking Treatment for Acute Migraine
Maple Grove, MN – November 18, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has added Zembrace® SymTouch® (sumatriptan) Injection 3 mg ... Read More
